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Organ transplant recipients frequently suffer from toxicity or from lack of efficacy of immunosuppressive drugs,
which can be attributed to individual variations in drug sensitivity. This problem can be resolved by applying
pharmacodynamic monitoring that focuses on measuring the biological effects of drugs. Here we discuss the new
technique called phospho-specific flow cytometry to monitor the activity of intracellular immune signaling
pathways at the single-cell level in whole blood samples. Through this tool the efficacy of immunosuppressive
medication can be assessed, novel targets can be identified, and differences in drug sensitivity between cells and
patients can be clarified.
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Background
To prevent and to treat alloreactivity, transplant recipients
are on immunosuppressive medication for life. These
drugs target the immune system in a non-specific manner
by affecting immune cell activation, clonal expansion and
differentiation. Standard immune suppressing regimens
consists of a calcineurin inhibitor (CNI, e.g., tacrolimus/
cyclosporine), an inosine monophosphate dehydrogenase
inhibitor (mycophenolate mofetil, MMF) and corticoster-
oids. The therapeutic window of CNIs is small, which
places patients at risk of toxicity in case of over-dosing
and rejection when under-dosed. Examples of debilitating
side effects of immunosuppressive medication are infec-
tions, diabetes, nephrotoxicity and malignancies, all influ-
encing patient and graft survival and quality of life.
Because of these debilitating side effects, there is a great
need for (1) safer and more selective immunosuppressive
agents and (2) better monitoring tools and parameters.* Correspondence: c.c.baan@erasmusmc.nl
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reproduction in any medium, provided the orIn the recent years, new pharmacologic agents have
been introduced in the transplantation clinic to more spe-
cifically target the molecules of the T-cell activation cas-
cade. Novel agents are drugs that target T-cell receptor
(TCR) signaling (e.g., sotrastaurin), co-stimulation path-
ways (belatacept) and cytokine signaling pathways (tofaci-
tinib). Based on the results found in experimental models,
it is expected that these novel immunosuppressants are
more specific than CNI.
Here we will touch briefly on the mechanisms of action
of these immunosuppressants and discuss the develop-
ments in pharmacodynamic monitoring in transplantation
patients.T-cell activation and intracellular signaling pathways:
targeting signal 1
After T-cell activation, several intracellular signaling path-
ways are used for proliferation, differentiation and death.
This involves a cascade of phosphorylation and depho-
sphorylation of intracellular molecules by phosphatases
(enzymes that remove phosphate groups from other
proteins) and kinases (enzymes that modify proteins by
adding phosphate groups).
In brief, TCR activation results in the activation of
tyrosine kinases of the Syk/Zap-70 family, Tec and Scrd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phorylate tyrosine residues located within immunorecep-
tor tyrosine-based activation motifs on the cytosolic side
of the TCR/CD3 complex by lymphocyte protein-
tyrosine kinase (Lck) followed by its phosphorylation
and activation by CD45 receptor tyrosine phosphatase.A
B
Figure 1 (A) The role of PKC in TCR-CD28-induced signaling in T cells
which enables activation of JNK and NF-κB. The PKC-mediated activation o
the TCR-CD28-mediated induction of gene transcription, leading to prolifer
subunits: α-chain (IL-2R; i.e., CD25), β-chain (IL-2Rß; CD122) and the commo
heterotrimer IL-2R initiates the activation of Janus-activated kinase 3 (JAK3)
phosphorylate tyrosine residues in the cytoplasmic part of IL-2Rβ and the γ
association of these tyrosine kinases and the signal transducer and activato
IL-2Rβ. Recruited STATs are phosphorylated by activated JAKs. Activated ST
interferons, e.g., (IFN)-γ, granzyme B, Fasligand (FasL), suppressors of cytokin
FOXP3 binding to DNA promoter sequences.Zap-70 is recruited to the TCR/CD3 complex where it
becomes activated, promoting recruitment and phos-
phorylation of downstream adaptor or scaffold proteins.
Zap-70 promotes recruitment of the molecule named
Vav and phosphorylates the linker for activated T cells
(LAT), a transmembrane and adaptor that links the TCR. In response to TCR-CD28 stimulation, PKC is recruited and activated,
f NFAT is controversial. Taken together, PKC plays the central role in
ation and cytokine secretion in T cells. (B) The IL-2R consists of three
n cytokine-receptor γ-chain (γc; CD132). Binding of IL-2 to the
, which associates with the γc, while JAK1 associates with IL-2Rβ. Both
c. Subsequently, the JAK molecules are activated, which amplifies the
r of transcription 5 (STAT5) or STAT3 with the cytoplasmic tail of
ATs translocate to the nucleus and activate gene transcription of
e signaling (SOCS) and the transcription factor for regulatory T cells:
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activation of the transcription factors, e.g., JNK, MAPK,
NF-κB, AP-1 and NF-AT [1-3]. For example, NF-κB acti-
vation is promoted by protein kinase C (PKC)θ, which
acts as an intermediate in the transduction of activation
by TCR receptor signaling and CD28 co-stimulation [4].
NF-κB in concert with the transcription factors NF-AT
and AP-1 contributes to interleukin (IL)-2 messenger
RNA transcription, a key molecule in the response to-
wards the allograft (Figure 1A).
Searching for selective immunosuppressive agents to
prevent and to treat allograft rejection, phase I and II
trials are running with immunosuppressive drugs that
target the NF-κB pathway. Particularly, the efficacy and
specificity of sotrastaurin (formerly named AEB071), a
low molecular mass synthetic compound that potently
inhibits all PKC isoforms is currently being studied in
kidney transplant patients (Table 1). The phase II trial of
sotrastaurin showed little benefit to renal graft function
with an excess of acute rejection episodes, gastrointes-
tinal disorders and serious infections when used as
maintenance therapy in combination with mycopheno-
late mofetil and steroids [5,6].
Co-stimulation: targeting signal 2
The co-stimulatory signal augments T-cell activation by
interactions with cell surface molecules expressed by
antigen-presenting cells (APC). In this respect, augment-
ing interactions are: CD40/CD40ligand, CD28/CD80
and/or CD28/CD86. Inversely, T-cell activation is
reduced by the co-stimulation molecule cytotoxic T-
lymphocyte antigen (CTLA)-4, which transmits a T-cellTable 1 Complications after organ transplantation and therap
Complications and
immune responses
Identified cell type Key s
Ischemia reperfusion
injury (IRI)
NK and NKT cells, neutrophils,
macrophages
NF-AT
MAPK
NF-κB
Hyper-acute rejection B- and plasma cells NF-AT
MAPK
Acute rejection Cells from the innate and adaptive
immune system
NF-AT
PKC, N
JAK1/
NF-κB
mTOR
Chronic rejection Memory T cells, NF-AT
MAPKB cells
Tolerance FoxP3+ regulatory T cells mTOR
CNI Calcineurin inhibitor.
IvIG Intravenous immune globulin.
rATG rabbit antithymocyte globulin.inhibitory signal after binding to CD80 and/or CD86.
The humanized receptor conjugate of CTLA-4 and
IgG1, CTLA-4 Ig (belatacept), which indirectly blocks
CD28 signaling, is approved for use in organ transplant-
ation. Blockade of CD28 activation prevents the activa-
tion of NF-κB activation, the transcriptional target for
co-stimulatory activity [7].
Two recently completed phase 3 trials of belatacept
(nulojixW) in kidney transplantation, the so-called BENE-
FIT and BENEFIT-EXT studies, indicate that this agent
is a safe and effective immunosuppressant leading to sig-
nificantly better renal function (GFR, glomerular filtra-
tion rate) as compared to a cyclosporine-based regimen
in kidney transplant recipients [8-10]. Acute rejection
rates were higher but clinically acceptable among
belatacept-treated patients (17-22% at 12 months in the
belatacept groups versus 7-14% in the cyclosporine
groups). While posttransplant lymphoproliferative dis-
ease was also more common in those on belatacept, this
was largely limited to previously EBV seronegative
recipients.
Cytokine signaling: targeting signal 3
The third option studied to treat organ transplant
patients with more selective immunosuppressive medi-
cation is targeting signal 3: the IL-2 signaling pathway.
Blockade of the IL-2 pathway prevents T-cell differenti-
ation and production of effector molecules. This
can now be achieved with the immunosuppressant
named tofacitinib, formerly known as CP-690,550 and
tasocitinib (Table 1). The Janus kinase (JAK)/signal
transducer and activator of the transcription (STAT)eutic options
ignaling molecule(s) of Therapeutic options
, NF-κB, STATs, T-cell depletion (rATG/alemtuzumab)
-p38, ERK, JNK
, AP-1
, NF-κB, AKT IvIG, T- and B-cell depletion (rATG,
alemtuzumab, rituximab), bortezomib-p38, ERK, JNK, AP-1
CNI
F-κB Sotrastaurin/AEB071,
3 tofacitinib/CP-690,550
Belatacept
Everolimus/sirolimus
T-cell depletion (rATG/alemtuzumab)
, NF-κB, AKT, PI3K,
-p38, ERK, JNK, AP-1
Anti-CD2 fusion protein (alefacept)
Depletion of memory T cells (efalizumab)
Everolimus/sirolimus
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cytokine-mediated signals of the IL-2 family members
(IL-2, IL-4, IL-7, IL-15, IL-21) to the nucleus in order
to alter gene expression programs [11]. JAKs possess
two near-identical phosphate-transferring domains ([12],
Figure 1B). One domain exhibits the kinase activity,
while the other negatively regulates the kinase activity of
the first. The four enzymes JAK1, JAK2, JAK3 and tyro-
sine kinase (TYK) 2 transduce cytokine-mediated sig-
nals. After recruitment, STATs are phosphorylated by
the JAKs at a specific activating tyrosine residue. This
results in dissociation from the receptor, formation of
STAT homo- or heterodimers, and translocation to the
nucleus. Seven STATs have been identified that after ac-
tivation interact with specific DNA sequences in target
promoters to modify gene expression [12]. For instance
IL-2 receptor signaling is mediated through activation of
JAK1 and JAK3 with subsequent phosphorylation and
activation of STAT3 and STAT5, which are key mole-
cules for T-cell development and activation.
Treatment with the JAK1/3 antagonist tofacitinib in
kidney transplant recipients demonstrated acceptable
safety and tolerability in combination with mycopheno-
late mofetil [13]. Tofacitinib-based treatment resulted in
relatively low acute rejection rates but was unfortunately
accompanied by high infection rates suggestive of over-
immunosuppression [14].Rational for pharmacodynamic immunomonitoring
Overall the novel immunosuppressants currently being
tested in phase II and III trials (sotrastaurin, tofacitinib)
and the FDA-approved belatacept failed to show potent,
selective immunosuppression. To gain insight into the
mechanisms behind these unexpected side effects and
the sometimes observed lack of efficacy, it is useful to
perform immune monitoring. This will give answers to
the questions about the selectivity and efficacy of these
novel immunosuppressive compounds. By immune
monitoring, questions like the following will be unrav-
eled: “Do the agents indeed block their target(s)
in vivo?” “How do naïve and antigen-experienced mem-
ory T cells behave?” “Do immunosuppressive agents in-
fluence the function of the suppressor regulatory T cells
(Tregs) that control immune reactivity?” “Does redun-
dancy in the cytokine network affect the efficacy of the
studied immunosuppressant?” Recent developments in
phospho-specific flow cytometry now provide the oppor-
tunity for routine measurements of intracellular signal-
ing molecules in different T-cell subsets. In the next part
of the article, we will discuss this tool with its recent
developments and applications to better determine the
balance between drug efficacy and side effects for the
individual patient.Immune monitoring by classical flow cytometry
Flow cytometry is the standard immune monitoring
method to measure T-, B- and NK-cell numbers in the
circulation of rATG/alemtuzumab-treated patients and
to verify CD25 blockade on T cells during basiliximab
therapy. Reports on these studies showed correlations
between cell numbers and the occurrence of opportunis-
tic infections and the malignancies without providing
insight on the function of the repopulated T cells and of
T cells covered with anti-CD25 mAb [15-18]. For in-
stance the infections in rATG-treated patients are
explained by the low T-cell and NK-cell numbers. How-
ever, there is now evidence that the function of the repo-
pulated T cells is impaired, which may affect the
immunity of rATG-treated patients [17-19]. Also the
role of regulatory T cells (Tregs) in clinical organ trans-
plantation is often studied by their phenotype. One of
the first papers describing a role for these cells in drug-
free tolerant kidney transplant patients was by Louis
et al., who reported high numbers of peripheral Tregs
compared to patients with chronic rejection [20]. In line
with effector T cells, also the numbers and function of
Tregs are influenced by immunosuppressive drugs
whereby both Treg-favoring and -hampering effects were
reported [21-25]. Also, the first studies analyzing the
mechanisms of action of tofacitinib and belatacept re-
port an effect on peripheral Treg numbers. A significant
decrease in Treg numbers with unexpected potent regu-
latory capacities of tofacitinib-treated patients was found
[26]. Additional information on why the suppressive
function was not influenced by tofacitinib or how rATG
triggers the induction of Tregs in vivo would have been
helpful to understand these findings.
Accordingly, there is a clear-cut need for methods that
provide information at the molecular level of immune
competent cells. A method that recently became avail-
able for clinical research and diagnostics and offers these
applications is phospho-specific flow cytometry. By this
method intracellular signaling pathways at the single-cell
level can be measured. It is a quick and reliable method
that combines the extracellular cell surface characteris-
tics with intracellular molecular activities and thus will
provide the additional information required for to better
understand T-cell functions during immune responses in
immunosuppressed transplantation patients.
Phospho-specific flow cytometry: a novel tool to measure
intracellular signaling pathways
With the recent advances in flow cytometry, the number
of parameters that can be measured has been largely
expanded. These new parameters now allow us to moni-
tor immune responses functionally at rest and following
activation at the single-cell level. This includes para-
meters such as ligand-induced activation, intracellular
Baan et al. Transplantation Research 2012, 1:20 Page 5 of 9
http://www.transplantationresearch.com/content/1/1/20cytokine production, cytotoxic and proliferative activ-
ities, and most recently intracellular signaling pathways.
The availability of phospho-specific antibodies makes it
possible to study protein phosphorylation at the post-
translation level, thereby influencing the activity of intra-
cellular proteins. Protocols have been developed that can
be used to study, in whole blood, cellular activation cas-
cades both in the presence and absence of agents that
stimulate or inhibit cellular functions. This approach will100 µl blood
30 min 37 °C
IL -15
-
IL -2
IL -7 FI
PE
LY
0.6 % 22.4 % 0.1 %
95.7 % 0.9 %
78.7 % 1.3 %
Neg cytokine                     250          
(2000 IU/ml)
CD3 
S
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A
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Figure 2 (A) Staining procedure of STAT5. Whole blood (100 μl) is sti
are lysed and white blood cells are fixed for 10 min at 37°C with Lyse/Fix B
FacsFlow buffer (BD Biosciences) and permeabilized with cold 70% methan
supplemented with 0.5% bovine serum albumin followed by standard stain
Whole blood stimulated for 30 min with IL-2, IL-7 and IL-15 (2,000 IU/ml) in
tofacitinib/CP-690,550. P-STAT5 expression by CD3 T cells.provide information on the dynamics of the immune
responses seen in organ transplant patients. But one
should be aware that this is only the beginning of this
new research area as more than 80,000 unique phos-
phorylations have been described in mammalian cells
(www.phosphosite.org).
Key complications that occur after transplantation are
ischemia reperfusion injury and acute- and chronic re-
jection (Table 1). The underlying mechanisms areFACS
P-STAT5
CD3
CD4
CD8X
RM
SE
0.1 % 1.6 % 5.4 %
39.3 % 88.4 % 94.3 %
9.5 % 48.0 % 65.7 %
100                           25                 10
Tofacitinib/CP-690,550  (ng/ml)
IL-2
IL-7
IL-15
mulated by IL-2, IL-7 or IL-15 for 30 min at 37°C. Red blood cells
uffer (BD Biosciences, San Jose, CA). Next, the cells are washed in
ol for 30 min at −20°C, washed twice in FacsFlow buffer
ing procedures for P-STAT5 (clone Y694), CD3, CD4 and CD8. (B)
the absence and presence of different concentrations of
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involved that interact with each other and with the
grafted tissue. Consequently, the therapeutic approach
differs between these clinically relevant complications.
As summarized in the table, many molecules participate
in transmitting signals. The immunosuppressive agents
tofacitinib and sotrastaurin were designed to specifically
target these molecules, JAK1/3 and PKCθ, respectively.
Others like the calcineurin inhibitors and mTOR inhibi-
tors, both isolated from fungi, also target intracellular
signaling molecules. One of the first papers showing the
potential of pharmacodynamic monitoring of mTOR in-
hibitor molecules was recently reported [27]. By whole
blood phospho-specific flow cytometry, rapamycin was
found to inhibit a downstream target of mTOR: the
phosphorylated S6 ribosomal protein. This assay may
have advantages over the existing mTOR activity tests,
which are far from reliable in predicting the efficacy of
sirolimus and everolimus. Proof that indeed the analysis
of the phosphorylated S6 ribosomal protein is useful for
clinical purposes has not been provided yet, but the
paper by Barten’s group using clinically relevant concen-
trations of sirolimus shows its potential for therapeutic
drug monitoring. A nice example demonstrating the
power of phospho-specific flow cytometry was given by
Wu et al., who reported STAT5 activation in NK cells
and T cells of melanoma patients who received a bolus
infusion of IL-2 [28]. It was speculated that the respon-
ders and non-responders to IL-2 treatment can be iden-
tified by STAT5 measurements of peripheral blood cells.
Further defective STAT1 phosphorylation was reportedM
F
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Figure 3 STAT5 phosphorylation by CD4+ T cells after whole blood a
tofacitinib/CP-690,550 therapy. Cytokine-activated P-STAT5 is plotted at
cytokine-stimulated P-STAT5 minus the MFI of the unstimulated sample.in lymphocytes from the majority of melanoma patients
vs. healthy individuals after treatment with type I inter-
feron [29]. And basal activation of STAT signaling and
reduced response to type I and II interferons, IL-2, IL-6
and IL-10, may be helpful to identify the activity and se-
verity of systemic lupus erythematosus [30]. In kidney
transplant patients, we analyzed the effects of the JAK1/
3 antagonist tofacitinib on IL-2-, IL-7- and IL-15-
triggered activation of STAT5 and found a dose-
dependent inhibition (Figure 2A and B). The whole
blood analysis of tofacitinib-treated patients nicely
showed inhibition of the IL-2-, IL-7- and IL-15-activated
P-STAT5. An example of P-STAT5 measured in CD4+ T
cells from a kidney transplant patient during tofacitinib
treatment is depicted in Figure 3. Phospho-specific flow
cytometry can also be used to study cross reactivity of
an immunosuppressive compound. For instance, tofaciti-
nib inhibits JAK2 activation, a pathway that plays a role
in hematopoiesis and may explain the mild anemia
observed in tofacitinib-treated patients [25,31]. Apart
from the analysis of typical target signaling molecules,
e.g., NF-κB in sotrastaurin-treated patients, mTOR in
sirolimus and p38 MAPK signaling in CNI-treated kid-
ney transplant patients, this phospho-specific flow cyto-
metry technique can also be used to study T-cell
function before and after rATG induction treatment and
to further unravel the mechanism of action of immuno-
suppressive agents like CNI [26,32]. For instance, we
used this technique to study the function of T cells after
rATG induction therapy and found impaired signal 3
responses by the memory T-cell population. Particularly transplantation
14 32 60 120
IL-2
IL-7
IL-15
ctivation with IL-2, IL-7 and IL-15 was inhibited in this patient on
the Y-axis as the median fluorescence intensity (MFI) of
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activation by P-STAT5 (Figure 4). This finding may help
to explain why rATG-treated patients often suffer from
severe viral infections. It is a combination of different
immune phenomena: (1). low T-cell numbers and (2)
impaired T-cell function. The latter finding shows the
strength of the phospho-flow technology: detection of
abnormal signaling signatures as an indicator for
impaired cellular function.
Challenges to clinical practice and limitations of
flow cytometry
The clinical applications for phospho-protein analysis by
flow cytometry are clear: the efficacy and side effects of
immunosuppressive drugs, pharmodynamic profiling,
cellular functions and disease activity. However, like any
other laboratory technique, also this method has its typ-
ical difficulties. A limitation is the availability of anti-
bodies of interest. Yet it is expected that more and more
phospho- and epitopic-specific antibodies will becomeCD45RO
C
C
R
7
Naive CM
EMEMRA
3 months after 
rATG induction therapy
Pre- transplantation
centra
A
B
Figure 4 (A) Example of the gating strategy used. CD4+ and CD8+ T c
CD45RO to define the naïve, effector memory (EM), central memory (CM) a
decreased IL-2-induced STAT5 phosphorylation after rATG therapy in CD8 c
memory T cells.available soon. For instance, antibodies that detect TCR-
induced T-cell activation would be highly valued. These
antibodies can be used to determine whether or not T
cells are present in the peripheral blood of organ trans-
plant patients that respond to donor antigen. Analysis of
activated Zap-70 will provide this key information and
will at the same time be the functional alternative that
overcomes the difficulties and limitations of TCR tetra-
mer flow cytometry [33]. Further, simultaneous measure-
ments of phosphorylated proteins together with
cytokines are far from optimal, and reproducibility from
one experiment to the next remains a problem. In this
respect, standardization of the instrument using multi-
color bead samples is helpful. Data interpretation is also
a question to address: should percentages or mean fluor-
esce intensities (MFI) be used. The relative MFI values
are based on control samples like the unstained control
samples, isotype control or fluorescent minus one con-
trol to set thresholds and are used to measure a shift in
fluorescence intensity of the entire cell populations.CD4 CD8
75%72%
28%65%
CD8
central memory 
CD4                    
l memory 
ells were analyzed for their cell surface expression of CCR7 and
nd effector memory RA + (EMRA) T-cell subsets. (B) Example of
entral memory T cells (CD45RO + CCR7+) and not in CD4 central
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cell population have changed expression of the molecule
of interest.
As stated in the paper by Herzenberg et al., interpret-
ing flow cytometry data is the ‘Tower of Babel’: negative,
unstained populations can seem to be positive and vice
versa [34]. Therefore, optimization and standardization
are key for the success of (phospho-specific) flow cyto-
metry for measuring immune responses in healthy and
diseased individuals. Addressing these limitations will
further improve the utility of phospho-specific flow cyto-
metry for clinical applications.
Conclusions
Recently, phospho-specific flow cytometry came forward
as a new and powerful tool to analyze the activity of
intracellular signaling pathways by rapid and sensitive
detection of intracellular phosphorylated proteins at the
single-cell level. It is a technique that can be used to
study (pathological) conditions in immune cells, can be
used as a screening tool to identify novel targets of im-
munosuppressive drugs and for pharmacodynamic mon-
itoring of patients on immunosuppressive medication. In
particular patients treated with drugs that target these
intracellular signaling molecules: the inhibitors of calci-
neurin, mTOR and kinase activity should be monitored
by phospho-specific flow cytometry.
Analysis of signaling pathways in large patient popula-
tions will show patient-specific differences in immune
reactivity, drug susceptibility and drug-related side
effects.
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